Phase II study of the PI3K inhibitor pilaralisib (SAR245408; XL147) in patients with advanced or recurrent endometrial carcinoma (Q38388678)

2 September 2017

Phase II study of the PI3K inhibitor pilaralisib (SAR245408; XL147) in patients with advanced or recurrent endometrial carcinoma (English)

1 reference

2 September 2017

Floor Backes

3

0 references

Ignace Vergote

2

object named as

Ignace Vergote

1 reference

2 September 2017

1

Ursula Matulonis

1 reference

2 September 2017

Lainie P Martin

4

1 reference

2 September 2017

Scott McMeekin

5

1 reference

2 September 2017

Michael Birrer

6

1 reference

2 September 2017

Frank Campana

7

1 reference

2 September 2017

Yi Xu

8

1 reference

2 September 2017

Coumaran Egile

9

1 reference

2 September 2017

Sharad Ghamande

10

1 reference

2 September 2017

language of work or name

English

0 references

publication date

17 December 2014

1 reference

2 September 2017

1 reference

2 September 2017

136

1 reference

2 September 2017

246-253

1 reference

2 September 2017

2

1 reference

2 September 2017

Cancer statistics, 2014

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.12.019

Trends in demographic and clinical characteristics in women diagnosed with corpus cancer and their potential impact on the increasing number of deaths.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.12.019

The molecular biology of endometrial cancers and the implications for pathogenesis, classification, and targeted therapies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.12.019

The PI3K/AKT/mTOR pathway as a therapeutic target in endometrial cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.12.019

Molecular and pathologic aspects of endometrial carcinogenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.12.019

Two pathogenetic types of endometrial carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.12.019

Integrated genomic characterization of endometrial carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.12.019

Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.12.019

Integrated genomic profiling of endometrial carcinoma associates aggressive tumors with indicators of PI3 kinase activation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.12.019

The PI3K pathway as drug target in human cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.12.019

High frequency of coexistent mutations of PIK3CA and PTEN genes in endometrial carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.12.019

PIK3CA gene mutations in endometrial carcinoma: correlation with PTEN and K-RAS alterations.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.12.019

Mutual exclusiveness between PIK3CA and KRAS mutations in endometrial carcinoma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.12.019

Everolimus as second- or third-line treatment of advanced endometrial cancer: ENDORAD, a phase II trial of GINECO.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.12.019

Ridaforolimus as a single agent in advanced endometrial cancer: results of a single-arm, phase 2 trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.12.019

Phase II study of temsirolimus in women with recurrent or metastatic endometrial cancer: a trial of the NCIC Clinical Trials Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.12.019

A phase 2 study of the oral mammalian target of rapamycin inhibitor, everolimus, in patients with recurrent endometrial carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.12.019

New strategies in endometrial cancer: targeting the PI3K/mTOR pathway--the devil is in the details

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.12.019

Phase I safety, pharmacokinetic, and pharmacodynamic study of SAR245408 (XL147), an oral pan-class I PI3K inhibitor, in patients with advanced solid tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.12.019

High-throughput detection of clinically relevant mutations in archived tumor samples by multiplexed PCR and next-generation sequencing.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.12.019

Phase I safety, pharmacokinetic, and pharmacodynamic study of the oral phosphatidylinositol-3-kinase and mTOR inhibitor BGT226 in patients with advanced solid tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.12.019

Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.12.019

A multicenter phase I trial of PX-866, an oral irreversible phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.12.019

Insulin resistance: a significant risk factor of endometrial cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.12.019

Molecular determinants of outcome with mammalian target of rapamycin inhibition in endometrial cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.12.019

Development of PI3K inhibitors: lessons learned from early clinical trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.12.019

Temsirolimus in combination with carboplatin and paclitaxel in patients with advanced solid tumors: a NCIC-CTG, phase I, open-label dose-escalation study (IND 179).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.12.019

Phase II trial of combination bevacizumab and temsirolimus in the treatment of recurrent or persistent endometrial carcinoma: a Gynecologic Oncology Group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.12.019

Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.12.019

10.1016/J.YGYNO.2014.12.019

7 January 2021

Identifiers

DOI

1 reference

2 September 2017

1 reference